AI and wearable tech aim to catch prediabetes before it starts

NCT ID NCT07386756

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 1,000 adults at high risk for prediabetes to see if continuous glucose monitors (CGMs) combined with artificial intelligence can detect the condition earlier and more accurately than current tests. Participants will wear a CGM and provide other health data. The goal is to build a smarter, personalized system for preventing diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

continuous glucose monitoring (CGM) device and AI-driven intervention platform

What this could lead to

If successful, this could lead to earlier and more accurate detection of prediabetes, allowing for personalized prevention strategies to delay or prevent diabetes.

What could go wrong

This is an early-stage observational study, not a treatment trial. The new diagnostic models may not prove more effective than current methods, and results may not apply to all populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prediabetes syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••